Results 111 to 120 of about 14,494 (232)

Hepatitis B Management in the Middle East: A Narrative Review of Current Antiviral Treatments

Gastrointestinal Disorders
Introduction: Chronic hepatitis B (CHB) is a significant public health issue worldwide, especially in the Middle East region. Around 8% to 20% of patients with CHB develop cirrhosis, which may progress to hepatocellular carcinoma.
Hannah Beck, Nishaanth Dalavaye, Kalaikshiga Kengadaran, Mosammath Monira Khatun, Ria Hitesh Patel, Taif Al-Rubaye, Laith Alrubaiy   +6 more
doaj   +1 more source

Bone mineral density optimisation in adults with perinatally acquired HIV infection in routine care [PDF]

, 2017
We report on BMD and factors associated with reductions in BMD for all adults with perinatally acquired HIV who attended a London clinic between May 2014 and October 2016.
Fidler, S, Foster, C, Fyles, F, Pasvol, TJ   +3 more
core  

Jefferson Digital Commons quarterly report: January-March 2020 [PDF]

, 2020
This quarterly report includes: New Look for the Jefferson Digital Commons Articles COVID-19 Working Papers Educational Materials From the Archives Grand Rounds and Lectures JeffMD Scholarly Inquiry Abstracts Journals and Newsletters Master of Public ...
Copeland, LIBT, James, Duinkerken, MSI, Kelsey, Gordon, MSLIS, MEd, MA, Larissa   +2 more
core   +1 more source

Using a single tablet regimen of darunavir, cobicistat, emcitrabine, and tenofovir alafenamide in virally suppressed HIV-1 patients is an adequate treatment option for controlling HIV [PDF]

, 2021
A clinical decision report using: Orkin C, Molina JM, Negredo E, et al. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine,
Kathuria, Priya
core   +1 more source

96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection

Journal of Hepatology, 2018
Tenofovir alafenamide (TAF) is a new prodrug of tenofovir developed to treat patients with chronic hepatitis B virus (HBV) infection at a lower dose than tenofovir disoproxil fumarate (TDF) through more efficient delivery of tenofovir to hepatocytes. In 48-week results from two ongoing, double-blind, randomized phase III trials, TAF was non-inferior to
Agarwal, Kosh, Brunetto, Maurizia, Seto, Wai Kay, Lim, Young-Suk, Fung, Scott, Marcellin, Patrick, Ahn, Sang Hoon, Izumi, Namiki, Chuang, Wan–Long, Bae, Ho, Sharma, Manoj, Janssen, Harry L. A., Pan, Calvin Q., Çelen, Mustafa Kemal, Furusyo, Norihiro, Shalimar, Dr, Yoon, Ki Tae, Trinh, Huy, Flaherty, John F., Gaggar, Anuj, Lau, Audrey H., Cathcart, Andrea L., Lin, Lanjia, Bhardwaj, Neeru, Suri, Vithika, Mani Subramanian, G., Gane, Edward J., Buti, Maria, Chan, Henry L. Y.   +28 more
openaire   +6 more sources

Tenofovir Alafenamide Fumarate: A New Tenofovir Prodrug for the Treatment of Chronic Hepatitis B Infection [PDF]

The Journal of Infectious Diseases, 2017
Tenofovir alafenamide fumarate (TAF), a new prodrug of tenofovir and a potential successor of tenofovir disoproxil fumarate (TDF), has been approved in the United States and Europe for treating adolescents and adults with chronic hepatitis B infection. TAF is formulated to deliver the active metabolite to target cells more efficiently than TDF at lower
Maria, Buti, Mar, Riveiro-Barciela, Rafael, Esteban   +2 more
openaire   +2 more sources

Three‐Year Long‐Term Outcomes in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab Treatment in Clinical Practice

Cancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Background Findings regarding long‐term outcomes of unresectable hepatocellular carcinoma (uHCC) patients treated with atezolizumab and bevacizumab (Atez/Bev) have yet to be reported. This study was performed to evaluate results regarding 3 year survival of such patients treated in real‐world clinical settings.
Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Tanaka, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Tomomitsu Matono, Hidekatsu Kuroda, Yutaka Yata, Hiroki Nishikawa, Michitaka Imai, Tomoko Aoki, Hironori Ochi, Hideyuki Tamai, Shohei Komatsu, Fujimasa Tada, Shinichiro Nakamura, Yoshiko Nakamura, Teruki Miyake, Osamu Yoshida, Kazuhiro Nouso, Asahiro Morishita, Norio Itokawa, Tomomi Okubo, Taeang Arai, Akemi Tsutsui, Takuya Nagano, Kazunari Tanaka, Takanori Matsuura, Yuichi Koshiyama, Yuki Kanayama, Hidenao Noritake, Hirayuki Enomoto, Kosuke Matsui, Masaki Kaibori, Takumi Fukumoto, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada, on behalf of the RELPEC Group and HCC 48 Group   +55 more
wiley   +1 more source

A United States HIV provider survey of antiretroviral therapy management in people living with HIV with co-occurring conditions

AIDS Research and Therapy
Introduction Simplified HIV treatment guidelines favor integrase strand transfer inhibitors (INSTIs). However, non-infectious comorbidities and co-occurring conditions (i.e.
Sonya Krishnan, Marina B. Martinez Rivera, Christopher K. Lippincott, Maunank Shah   +3 more
doaj   +1 more source

Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort

BMC Infectious Diseases, 2019
Background Tenofovir alafenamide (TAF)-containing combinations were introduced in Switzerland after October 2016 and are recommended over tenofovir disoproxil fumarate (TDF) in patients with osteoporosis or impaired renal function.
Bernard Surial, Matthias Cavassini, Alexandra Calmy, Jan Fehr, Marcel Stöckle, Enos Bernasconi, Bianca Roth, Christoph A. Fux, Helen Kovari, Hansjakob Furrer, Andri Rauch, Gilles Wandeler, the Swiss HIV Cohort Study   +12 more
doaj   +1 more source

Effect of Testosterone Therapy on Cytochrome P450 3A and P‐Glycoprotein Activities Using Midazolam and Digoxin as Probe Substrates Among Transgender Adults

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 46, Issue 2, February 2026.
ABSTRACT Background Gender‐affirming testosterone therapy is one part of the standard of care for more than 1 million transgender adults in the United States. Testosterone therapy may influence the activities of drug‐metabolizing enzymes and transporters, but knowledge about its effect on the pharmacokinetics of other medications is limited.
Michiko Hunter, Rene Coig, Linda Risler, Kristen K. Patton, Radhika R. Narla, Dina N. Greene, Alson K. Burke, Elizabeth Micks, Mary F. Hebert, Lauren R. Cirrincione   +9 more
wiley   +1 more source